ClinicalTrials.gg
TerminatedNCT05665088Updated Oct 1, 2026Results posted

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

A Phase 3 interventional study of BXCL501 and Matching Placebo in Agitation and Dementia, sponsored by BioXcel Therapeutics Inc. Terminated at 7 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Primary conditionDementiaRegistry: Psychomotor AgitationReclassifiedWhy we changed it
Registry
Psychomotor Agitation — the first condition term the registry derived for this study.
ClinicalTrials.gg
Dementia
Why
  1. The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated for business reasons; not due to safety or efficacy concerns
Updated Oct 1, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,051 studies in Dementia with a site in United States — 213 open to participants now, 278 under way, 15 of them phase 3. Dementia · United States.

Enrollment
767th of 847
13 · median 93
Started
2022
with 87 others
Phase 3
58 of 1,051
4 open now
Registered
776th of 1,051
by date

Among the 1,051 studies in Dementia with a site in United States, this one is the 767th largest by enrollment of the 847 interventional ones that give a count, is one of 88 that started in 2022, is one of 58 in phase 3, and was the 776th registered.

Dementia

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

Browse Dementia studies →

Open to participants now

213 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 383 Dementia studies recruiting now, 244 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 164 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,051 studies in Dementia with a site in United States, or all of them as a file.
02

Study summary

A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.

Read the detailed description

A randomized, double-blind, placebo-controlled, parallel group, 3-arm study assessing efficacy, safety, and tolerability of two doses of BXCL501 in male and female participants (65 years and older) with acute psychomotor agitation associated with dementia.

Approximately 150 participants will participate in this study. Participants will receive a single film consisting of BXCL501 40 micrograms (µg) dose or BXCL501 60 µg dose or placebo. Participants must reside in a care facility where all study-related procedures and study drug dosing will be performed.

03

Conditions studied

  • Agitation
  • Dementia

Browse trials for

04

In context

Dementia Reclassified

2,375 studies on the registry are indexed under Dementia; 574 are open to participants now.

This study's enrollment of 13 is below the median of 90 across 1,761 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.

Compared within Dementia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psychomotor Agitation. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All participants must have a diagnosis of probable Alzheimer's disease (AD) based on National Institute on Aging and Alzheimer's Association (NIA-AA) criteria (2018). If participant biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria
  2. Episodes of psychomotor agitation (e.g., kick, bite, flailing)
  3. Participants exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the participant's usual behavior
  4. A score of 0 to 20 on the (MMSE) and require moderate to full assistance with activities of daily living
  5. Participants who read, understand, and provide written , or who have a legally authorized representative (LAR) to provide consent on their behalf
  6. Participants who are deemed to be medically appropriate for study participation by the principal investigator
  7. Participants who agree to use a medically acceptable and effective method

Exclusion criteria

Exclusion Criteria:

  1. Participants with dementia or other memory impairment not due to probable AD.
  2. Clinical diagnosis of probable AD should not be applied when there is evidence of a cerebrovascular incident temporally related to the worsening of cognitive function.
  3. Participants with agitation caused by acute intoxication.
  4. Participants with significant risk of suicide or homicide per the investigator's assessment.
  5. Participants who are medically unstable or in recovery. Note: Participants with a remote (>5 years) history of stroke may be included, regardless of size/location.
  6. History of syncope or syncopal attacks, orthostatic hypotension within the past 2 years, current evidence of hypovolemia, orthostatic hypotension, bradycardia.
  7. Participants with laboratory or (ECG) abnormalities.
  8. Participants who have received an drug within 30 days prior to Screening.
  9. Participants who are currently suffering from substance abuse.
  10. Participants with a potential cause for delirium (relatively recent onset agitation and dementia)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    BXCL501: 40 μg

    Participants will receive 40 μg of BXCL501 sublingually or buccally, with up to 2 doses permitted per calendar day over the 12-week treatment period.

    Drug: BXCL501

  • Experimental
    BXCL501: 60 μg

    Participants will receive 60 μg of BXCL501 sublingually or buccally, with up to 2 doses permitted per calendar day over the 12-week treatment period.

    Drug: BXCL501

  • Placebo comparator
    Placebo

    Participants will receive placebo-matched to BXCL501 with up to 2 doses permitted per calendar day over the 12-week treatment period.

    Drug: Matching Placebo

Interventions

  • Solid-dose film administered sublingually or buccally

    Also known as: Dexmedetomidine

  • DrugMatching Placebo

    Matching solid-dose film administered sublingually or buccally

07

What researchers measure

Primary outcomes

  1. Change From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 30 minutes post-dose

  2. Change From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 1 hour post-dose

  3. Change From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 2 hours post-dose

  4. Change From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 4 hours post-dose

  5. Change From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 8 hours post-dose

  6. Change From Pre-dose in PEC Total Score at 12 Hours Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 12 hours post-dose

  7. Change From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of Agitation

    The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 24 hours post-dose

Secondary outcomes

  1. Change From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of Agitation

    The PAS is an instrument based on direct observations of the participant that is developed to monitor the severity of agitation associated with dementia. The PAS is the sum of 4 behavior groups observed (aberrant vocalization, motor agitation, aggressiveness, resisting care, each behavior group ranging from 0 \[not present\] to 4 \[maximally present\]), and thus total score ranges from 0 (absence of agitation) to 16 (extremely severe). Lower score indicated better outcome.

    Time frame: Pre-dose, 2 hours post-dose

  2. Change From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of Agitation

    The CGI-S was used to rate the severity of agitation. The score ranges from 0 to 4 that comprises of, 0=not assessed; 1=normal, not at all symptomatic; 2=mildly symptomatic-low level of symptoms-little interference in social functioning; 3=moderately symptomatic-some prominent symptoms-some interference in functioning; 4=severely symptomatic- very marked symptoms make it difficult for participants to engage with others. Higher scores indicate greater severity of agitation.

    Time frame: Pre-dose, 2 hours post-dose

  3. Clinical Global Impression of Improvement (CGI-I) Score at 30 Minutes, 1 Hour, and 2 Hours Post-dose for the First Treated Episodes of Agitation

    The CGI-I is a global measure of improvement or change from baseline in participant's condition. The CGI-I score ranges from 0 to 7 that comprises of 0 = not assessed (missing), 1= very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, and 7= very much worse. Higher scores indicate worse condition.

    Time frame: 30 minutes, 1 hour, and 2 hours post-dose

  4. Change From Pre-dose in Agitation-Calmness Evaluation Scale (ACES) Scores at 1, 2, 4, and 8 Hours Post-dose for the First Episode of Agitation.

    The ACES is a single-item clinician-rated measure of agitation and sedation. Scores range from 1 to 9, where 1= marked agitation, 2= moderate agitation, 3= mild agitation, 4= normal behavior, 5= mild calmness, 6= moderate calmness, 7= marked calmness, 8= deep sleep, and 9= unarousable. Higher scores indicate greater levels of calmness and sedation.

    Time frame: Pre-dose, 1, 2 , 4 and 8 hours post-dose

  5. Number of Treated Episodes of Agitation After the First Treated Episode

    Time frame: Up to 12 weeks

08

Results

Posted Oct 1, 2026
Limitations and caveats
Study was terminated for business reasons; not due to safety or efficacy concerns.

Participant flow

The study was conducted in United States from 05-Dec-2022 to 11-Sep-2023.

Participant flow — Overall Study
MilestoneBXCL501: 40 μgBXCL501: 60 μgPlacebo
Started535
Completed435
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

PrimaryChange From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items the PEC total score, ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 30 minutes post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of Agitation-4.2 ± 2.28-3.0 ± 0.00-6.8 ± 5.81
PrimaryChange From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 1 hour post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of Agitation-6.4 ± 2.07-5.7 ± 1.53-6.0 ± 5.79
PrimaryChange From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 2 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of Agitation-4.4 ± 5.13-3.3 ± 3.51-5.2 ± 8.56
PrimaryChange From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 4 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of Agitation-12.0-11.0-15.3 ± 2.31
PrimaryChange From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 8 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of Agitation-20.0—-12.0
PrimaryChange From Pre-dose in PEC Total Score at 12 Hours Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 12 hours post-dose

No measurements were reported for this outcome.

PrimaryChange From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of Agitation

The PEC includes 5 items-poor impulse control, tension, hostility, uncooperativeness, and excitement-each of which is rated from 1 (minimum) to 7 (maximum); the sum of these 5 items, the PEC total score ranges from 5 (absence of agitation) to 35 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 24 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of Agitation-12.0-5.0-8.5 ± 7.78
SecondaryChange From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of Agitation

The PAS is an instrument based on direct observations of the participant that is developed to monitor the severity of agitation associated with dementia. The PAS is the sum of 4 behavior groups observed (aberrant vocalization, motor agitation, aggressiveness, resisting care, each behavior group ranging from 0 \[not present\] to 4 \[maximally present\]), and thus total score ranges from 0 (absence of agitation) to 16 (extremely severe). Lower score indicated better outcome.

Time frame:
Pre-dose, 2 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of Agitation-3.2 ± 2.28-2.3 ± 1.15-3.0 ± 4.24
SecondaryChange From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of Agitation

The CGI-S was used to rate the severity of agitation. The score ranges from 0 to 4 that comprises of, 0=not assessed; 1=normal, not at all symptomatic; 2=mildly symptomatic-low level of symptoms-little interference in social functioning; 3=moderately symptomatic-some prominent symptoms-some interference in functioning; 4=severely symptomatic- very marked symptoms make it difficult for participants to engage with others. Higher scores indicate greater severity of agitation.

Time frame:
Pre-dose, 2 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of Agitation-0.8 ± 0.84-0.3 ± 0.58-0.6 ± 1.14
SecondaryClinical Global Impression of Improvement (CGI-I) Score at 30 Minutes, 1 Hour, and 2 Hours Post-dose for the First Treated Episodes of Agitation

The CGI-I is a global measure of improvement or change from baseline in participant's condition. The CGI-I score ranges from 0 to 7 that comprises of 0 = not assessed (missing), 1= very much improved, 2= much improved, 3= minimally improved, 4= no change, 5= minimally worse, 6= much worse, and 7= very much worse. Higher scores indicate worse condition.

Time frame:
30 minutes, 1 hour, and 2 hours post-dose
Reported as:
Mean · score on a scale
Clinical Global Impression of Improvement (CGI-I) Score at 30 Minutes, 1 Hour, and 2 Hours Post-dose for the First Treated Episodes of Agitation
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
30 min Post-dose2.6 ± 0.553.3 ± 0.582.2 ± 1.10
1 hour Post-dose2.0 ± 0.002.3 ± 0.582.6 ± 2.07
2 hours Post-dose2.8 ± 0.843.0 ± 1.003.0 ± 2.35
SecondaryChange From Pre-dose in Agitation-Calmness Evaluation Scale (ACES) Scores at 1, 2, 4, and 8 Hours Post-dose for the First Episode of Agitation.

The ACES is a single-item clinician-rated measure of agitation and sedation. Scores range from 1 to 9, where 1= marked agitation, 2= moderate agitation, 3= mild agitation, 4= normal behavior, 5= mild calmness, 6= moderate calmness, 7= marked calmness, 8= deep sleep, and 9= unarousable. Higher scores indicate greater levels of calmness and sedation.

Time frame:
Pre-dose, 1, 2 , 4 and 8 hours post-dose
Reported as:
Mean · score on a scale
Change From Pre-dose in Agitation-Calmness Evaluation Scale (ACES) Scores at 1, 2, 4, and 8 Hours Post-dose for the First Episode of Agitation.
score on a scaleBXCL501: 40 μgBXCL501: 60 μgPlacebo
Change at 1 hour Post-dose0.6 ± 0.550.7 ± 0.581.0 ± 1.22
Change at 2 hours Post-dose0.6 ± 0.890.3 ± 0.580.8 ± 1.48
Change at 4 hours Post-dose2.02.02.3 ± 0.58
Change at 8 hours Post-dose7.0—2.0
SecondaryNumber of Treated Episodes of Agitation After the First Treated Episode
Time frame:
Up to 12 weeks
Reported as:
Number · Number of agitation episodes
Number of Treated Episodes of Agitation After the First Treated Episode
Number of agitation episodesBXCL501: 40 μgBXCL501: 60 μgPlacebo
Number of Treated Episodes of Agitation After the First Treated Episode575859

Adverse events

Collected over From first dose of study drug up to 30 days after the last dose (maximum duration:16 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BXCL501: 40 μg0/5 (0%)0/5 (0%)2/5 (40%)
BXCL501: 60 μg0/3 (0%)1/3 (33.3%)3/3 (100%)
Placebo0/5 (0%)1/5 (20%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventBXCL501: 40 μgBXCL501: 60 μgPlacebo
AgitationPsychiatric disorders0/51/30/5
PneumoniaInfections and infestations0/50/31/5
Most frequent other events
Showing 10 of 16
Most frequent other events
EventBXCL501: 40 μgBXCL501: 60 μgPlacebo
BradycardiaCardiac disorders2/50/30/5
Gait disturbanceGeneral disorders0/51/30/5
OedemaGeneral disorders0/51/30/5
DysphoniaRespiratory, thoracic and mediastinal disorders0/51/30/5
FallInjury, poisoning and procedural complications0/50/31/5
Abdominal painGastrointestinal disorders0/50/31/5
Skin irritationSkin and subcutaneous tissue disorders0/50/31/5
DiarrhoeaGastrointestinal disorders0/50/31/5
Upper respiratory tract infectionInfections and infestations0/50/31/5
CellulitisInfections and infestations0/50/31/5

Baseline characteristics

Safety Population: All participants who received at least 1 dose of study drug, with participants classified according to the drug actually received.

Age, Continuous
Age, Continuous(years)BXCL501: 40 μgBXCL501: 60 μgPlaceboTotal
Mean84.6 ± 4.8389.3 ± 3.5182.4 ± 8.7384.8 ± 6.54
Sex: Female, Male
Sex: Female, Male(Participants)BXCL501: 40 μgBXCL501: 60 μgPlaceboTotal
Female4329
Male1034
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BXCL501: 40 μgBXCL501: 60 μgPlaceboTotal
Hispanic or Latino0101
Not Hispanic or Latino52512
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BXCL501: 40 μgBXCL501: 60 μgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White53513
More than one race0000
Unknown or Not Reported0000
Positive and Negative Syndrome Scale - Excited Component (PEC) Total Score at Pre-dose
Positive and Negative Syndrome Scale - Excited Component (PEC) Total Score at Pre-dose(score on a scale)BXCL501: 40 μgBXCL501: 60 μgPlaceboTotal
Mean19.4 ± 3.9123.0 ± 8.1920.6 ± 1.5220.7 ± 4.37
09

Study locations

7 sites
  • BioXcel Clinical Research Site
    Los Alamitos, California 90720, United States
  • BioXcel Clinical Research Site
    Daytona Beach, Florida 32117, United States
  • BioXcel Clinical Research Site
    Maitland, Florida 32751, United States
  • BioXcel Clinical Research Site
    The Villages, Florida 32162, United States
  • BioXcel Clinical Research Site
    Marrero, Louisiana 70072, United States
  • BioXcel Clinical Research Site
    Springfield, Massachusetts 01103, United States
  • BioXcel Clinical Research Site
    Toms River, New Jersey 08755, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Sep 2023, 9 months.

Results were first posted in Oct 2026, 3 years after primary completion. A results delay was requested in Dec 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2022
First posted
Dec 27, 2022
StartActual
Dec 5, 2022
Primary completionActual
Sep 11, 2023
CompletionActual
Sep 11, 2023
Results delay requested
Dec 4, 2023
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Start date
Dec 14, 2022→Dec 5, 2022
Oct 1, 2026
Eligibility
4 inclusion criteria edited; 8 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAll subjectsparticipants must have a diagnosis of probable Alzheimer's disease (AD) based on National Institute on Aging and Alzheimer's Association (NIA-AA) criteria (2018). If subjectparticipant biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria
  • EditedSubjectsParticipants exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subjectparticipant's usual behavior
  • EditedSubjectsParticipants who read, understand, and provide written informed consent, or who have a legally authorized representative (LAR) to provide consent on their behalf
  • EditedSubjectsParticipants who are deemed to be medically appropriate for study participation by the principal investigator
Exclusion criteria
  • EditedSubjectsParticipants with dementia or other memory impairment not due to probable AD.
  • EditedSubjectsParticipants with agitation caused by acute intoxication.
  • EditedSubjectsParticipants with significant risk of suicide or homicide per the investigator's assessment.
  • EditedSubjectsParticipants who are medically unstable or in recovery. Note: SubjectsParticipants with a remote (>5 years) history of stroke may be included, regardless of size/location.
  • EditedSubjectsParticipants with laboratory or electrocardiogram (ECG) abnormalities.
  • EditedSubjectsParticipants who have received an investigational drug within 30 days prior to Screening.
  • EditedSubjectsParticipants who are currently suffering from substance abuse.
  • EditedSubjectsParticipants with a potential cause for delirium (relatively recent onset agitation and dementia)
Oct 1, 2026
Interventions
Arms added: BXCL501: 40 μg·BXCL501: 60 μg; arms removed: Cohort 1- 40 Micrograms·Cohort 2- 60 Micrograms
Oct 1, 2026
Primary outcomes
7 added, 1 removed
What changed in the outcomes
  • AddedChange From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 30 minutes post-dose
  • AddedChange From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 1 hour post-dose
  • AddedChange From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 2 hours post-dose
  • AddedChange From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 4 hours post-dose
  • AddedChange From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 8 hours post-dose
  • AddedChange From Pre-dose in PEC Total Score at 12 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 12 hours post-dose
  • AddedChange From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 24 hours post-dose
  • RemovedChange from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total scoreTime frame: 120 minutes post-dose for first episode of agitation
Oct 1, 2026
Documents
Secondary outcomes
5 added, 2 removed
What changed in the outcomes
  • AddedChange From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of AgitationTime frame: Pre-dose, 2 hours post-dose
  • AddedChange From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of AgitationTime frame: Pre-dose, 2 hours post-dose
  • AddedClinical Global Impression of Improvement (CGI-I) Score at 30 Minutes, 1 Hour, and 2 Hours Post-dose for the First Treated Episodes of AgitationTime frame: 30 minutes, 1 hour, and 2 hours post-dose
  • AddedChange From Pre-dose in Agitation-Calmness Evaluation Scale (ACES) Scores at 1, 2, 4, and 8 Hours Post-dose for the First Episode of Agitation.Time frame: Pre-dose, 1, 2 , 4 and 8 hours post-dose
  • AddedNumber of Treated Episodes of Agitation After the First Treated EpisodeTime frame: Up to 12 weeks
  • RemovedChange from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total scoreTime frame: 60 minutes post-dose for first episode of agitation
  • RemovedChange from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total scoreTime frame: 30 minutes post-dose for first episode of agitation
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    Start date Dec 14, 2022→Dec 5, 2022
    Eligibility 4 inclusion criteria edited; 8 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAll subjectsparticipants must have a diagnosis of probable Alzheimer's disease (AD) based on National Institute on Aging and Alzheimer's Association (NIA-AA) criteria (2018). If subjectparticipant biomarker data are unavailable, per the 2018 NIA-AA diagnostic criteria, the clinical diagnosis of probable AD will be based on the 2011 NIA-AA criteria
    • EditedSubjectsParticipants exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subjectparticipant's usual behavior
    • EditedSubjectsParticipants who read, understand, and provide written informed consent, or who have a legally authorized representative (LAR) to provide consent on their behalf
    • EditedSubjectsParticipants who are deemed to be medically appropriate for study participation by the principal investigator
    Exclusion criteria
    • EditedSubjectsParticipants with dementia or other memory impairment not due to probable AD.
    • EditedSubjectsParticipants with agitation caused by acute intoxication.
    • EditedSubjectsParticipants with significant risk of suicide or homicide per the investigator's assessment.
    • EditedSubjectsParticipants who are medically unstable or in recovery. Note: SubjectsParticipants with a remote (>5 years) history of stroke may be included, regardless of size/location.
    • EditedSubjectsParticipants with laboratory or electrocardiogram (ECG) abnormalities.
    • EditedSubjectsParticipants who have received an investigational drug within 30 days prior to Screening.
    • EditedSubjectsParticipants who are currently suffering from substance abuse.
    • EditedSubjectsParticipants with a potential cause for delirium (relatively recent onset agitation and dementia)
    Primary outcomes 7 added, 1 removed
    What changed in the outcomes
    • AddedChange From Pre-dose in PEC Total Score at 30 Minutes Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 30 minutes post-dose
    • AddedChange From Pre-dose in PEC Total Score at 1 Hour Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 1 hour post-dose
    • AddedChange From Pre-dose in PEC Total Score at 2 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 2 hours post-dose
    • AddedChange From Pre-dose in PEC Total Score at 4 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 4 hours post-dose
    • AddedChange From Pre-dose in PEC Total Score at 8 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 8 hours post-dose
    • AddedChange From Pre-dose in PEC Total Score at 12 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 12 hours post-dose
    • AddedChange From Pre-dose in PEC Total Score at 24 Hours Post-dose for the First Treated Episode of AgitationTime frame: Pre-dose, 24 hours post-dose
    • RemovedChange from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total scoreTime frame: 120 minutes post-dose for first episode of agitation
    Secondary outcomes 5 added, 2 removed
    What changed in the outcomes
    • AddedChange From Pre-dose in Pittsburgh Agitation Scale (PAS) Total Score at 2 Hours Post-dose for the First Episode of AgitationTime frame: Pre-dose, 2 hours post-dose
    • AddedChange From Pre-dose in Clinical Global Impression of Severity (CGI-S) Score at 2 Hours Post-dose for the First Episode of AgitationTime frame: Pre-dose, 2 hours post-dose
    • AddedClinical Global Impression of Improvement (CGI-I) Score at 30 Minutes, 1 Hour, and 2 Hours Post-dose for the First Treated Episodes of AgitationTime frame: 30 minutes, 1 hour, and 2 hours post-dose
    • AddedChange From Pre-dose in Agitation-Calmness Evaluation Scale (ACES) Scores at 1, 2, 4, and 8 Hours Post-dose for the First Episode of Agitation.Time frame: Pre-dose, 1, 2 , 4 and 8 hours post-dose
    • AddedNumber of Treated Episodes of Agitation After the First Treated EpisodeTime frame: Up to 12 weeks
    • RemovedChange from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total scoreTime frame: 60 minutes post-dose for first episode of agitation
    • RemovedChange from baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) total scoreTime frame: 30 minutes post-dose for first episode of agitation
    Interventions Arms added: BXCL501: 40 μg·BXCL501: 60 μg; arms removed: Cohort 1- 40 Micrograms·Cohort 2- 60 Micrograms
    + 5 other changes: index terms, identifiers, verification date, registry dates and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05665088
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Dec 27, 2022
Start date
Dec 5, 2022
Primary completion
Sep 11, 2023
Completion
Sep 11, 2023
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Study contacts

Robert Risinger, MD
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion